glp 1 agonist new drug Non-insulin injectable antidiabetic drugs - GLP-1 agonists and amylinomimetics GLP-1 Receptor Agonists and Research

PMID: 23668832 Bilton D, Schofield D, Mei G, Kay P.M, Bottiglieri T, Braganza J.M

Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications

A clinical trial was undertaken involving seven individuals with schizophrenia who received an oral dosage of SFN at 30 mg per day for a duration of 8 weeks

All animals were female littermates